Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
Elsevier Science
2019
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/23472/1/23472.pdf |
| _version_ | 1824416896843251712 |
|---|---|
| author | Akkerman, Onno Aleksa, Alena Alffenaar, Jan Willem Al-Marzouqi, Nada Hassan Arias Guillén, Miguel Belilovski, Evgeny Bernal, Enrique Boeree, Martin J. Borisov, Sergey Bruchfeld, Judith Cadiñanos Loidi, Julen Cai, Qingshan Caminero, Jose A. Cebrian Gallardo, Jose Joaquín Centis, Rosella Codecasa, Luigi Ruffo D’Ambrosio, Lia Dalcolmo, Margareth Pretti Danila, Edvardas Dara, Masoud Davidavičienė, Edita Davies Forsman, Lina De Los Rios Jefe, Jorge Denholm, Justin Duarte, Raquel Elamin, Seifeldin Eltaeb Ferrarese, Maurizio Filippov, Alexey Ganatra, Shashank Garcia, Ana García García, José María Gayoso, Regina Giraldo Montoya, Angela Maria Gómez Rosso, Roscio Gómez Gualano, Gina Hoefsloot, Wouter Ilievska Poposka, Biljana Jonsson, Jerker Khimova, Elena Kuksa, Liga Kunst, Heinke Laniado Laborín, Rafael Li, Yang Magis Escurra, Cecile Manfrin, Vinicio Manga, Selene Marchese, Valentina Martínez Robles, Elena Maryandyshev, Andrei Matteelli, Alberto Migliori, Giovanni Battista Mullerpattan, Jai B. Muñoz Torrico, Marcela Mustafa Hamdan, Hamdan Nieto Marcos, Magnolia Noordin, Noorliza Mohamad Palmero, Domingo Juan Palmieri, Fabrizio Payen, Marie Christine Piubello, Alberto Pontali, Emanuele Pontarelli, Agostina Quirós, Sarai Rendón, Adrián Skrahina, Alena Smite, Agnese Solovic, Ivan Sotgiu, Giovanni Souleymane, Mahamadou Bassirou Spanevello, Antonio Stošić, Maja Tadolini, Marina Tiberi, Simon Udwadia, Zarir Farokh Van den Boom, Martin Vescovo, Marisa Viggiani, Pietro Visca, Dina Zhurkin, Dmitry Zignol, Matteo |
| author_facet | Akkerman, Onno Aleksa, Alena Alffenaar, Jan Willem Al-Marzouqi, Nada Hassan Arias Guillén, Miguel Belilovski, Evgeny Bernal, Enrique Boeree, Martin J. Borisov, Sergey Bruchfeld, Judith Cadiñanos Loidi, Julen Cai, Qingshan Caminero, Jose A. Cebrian Gallardo, Jose Joaquín Centis, Rosella Codecasa, Luigi Ruffo D’Ambrosio, Lia Dalcolmo, Margareth Pretti Danila, Edvardas Dara, Masoud Davidavičienė, Edita Davies Forsman, Lina De Los Rios Jefe, Jorge Denholm, Justin Duarte, Raquel Elamin, Seifeldin Eltaeb Ferrarese, Maurizio Filippov, Alexey Ganatra, Shashank Garcia, Ana García García, José María Gayoso, Regina Giraldo Montoya, Angela Maria Gómez Rosso, Roscio Gómez Gualano, Gina Hoefsloot, Wouter Ilievska Poposka, Biljana Jonsson, Jerker Khimova, Elena Kuksa, Liga Kunst, Heinke Laniado Laborín, Rafael Li, Yang Magis Escurra, Cecile Manfrin, Vinicio Manga, Selene Marchese, Valentina Martínez Robles, Elena Maryandyshev, Andrei Matteelli, Alberto Migliori, Giovanni Battista Mullerpattan, Jai B. Muñoz Torrico, Marcela Mustafa Hamdan, Hamdan Nieto Marcos, Magnolia Noordin, Noorliza Mohamad Palmero, Domingo Juan Palmieri, Fabrizio Payen, Marie Christine Piubello, Alberto Pontali, Emanuele Pontarelli, Agostina Quirós, Sarai Rendón, Adrián Skrahina, Alena Smite, Agnese Solovic, Ivan Sotgiu, Giovanni Souleymane, Mahamadou Bassirou Spanevello, Antonio Stošić, Maja Tadolini, Marina Tiberi, Simon Udwadia, Zarir Farokh Van den Boom, Martin Vescovo, Marisa Viggiani, Pietro Visca, Dina Zhurkin, Dmitry Zignol, Matteo |
| author_sort | Akkerman, Onno |
| collection | Repositorio Institucional |
| description | The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline |
| format | Article |
| id | eprints-23472 |
| institution | UANL |
| language | English |
| publishDate | 2019 |
| publisher | Elsevier Science |
| record_format | eprints |
| spelling | eprints-234722024-12-10T20:07:47Z http://eprints.uanl.mx/23472/ Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study Akkerman, Onno Aleksa, Alena Alffenaar, Jan Willem Al-Marzouqi, Nada Hassan Arias Guillén, Miguel Belilovski, Evgeny Bernal, Enrique Boeree, Martin J. Borisov, Sergey Bruchfeld, Judith Cadiñanos Loidi, Julen Cai, Qingshan Caminero, Jose A. Cebrian Gallardo, Jose Joaquín Centis, Rosella Codecasa, Luigi Ruffo D’Ambrosio, Lia Dalcolmo, Margareth Pretti Danila, Edvardas Dara, Masoud Davidavičienė, Edita Davies Forsman, Lina De Los Rios Jefe, Jorge Denholm, Justin Duarte, Raquel Elamin, Seifeldin Eltaeb Ferrarese, Maurizio Filippov, Alexey Ganatra, Shashank Garcia, Ana García García, José María Gayoso, Regina Giraldo Montoya, Angela Maria Gómez Rosso, Roscio Gómez Gualano, Gina Hoefsloot, Wouter Ilievska Poposka, Biljana Jonsson, Jerker Khimova, Elena Kuksa, Liga Kunst, Heinke Laniado Laborín, Rafael Li, Yang Magis Escurra, Cecile Manfrin, Vinicio Manga, Selene Marchese, Valentina Martínez Robles, Elena Maryandyshev, Andrei Matteelli, Alberto Migliori, Giovanni Battista Mullerpattan, Jai B. Muñoz Torrico, Marcela Mustafa Hamdan, Hamdan Nieto Marcos, Magnolia Noordin, Noorliza Mohamad Palmero, Domingo Juan Palmieri, Fabrizio Payen, Marie Christine Piubello, Alberto Pontali, Emanuele Pontarelli, Agostina Quirós, Sarai Rendón, Adrián Skrahina, Alena Smite, Agnese Solovic, Ivan Sotgiu, Giovanni Souleymane, Mahamadou Bassirou Spanevello, Antonio Stošić, Maja Tadolini, Marina Tiberi, Simon Udwadia, Zarir Farokh Van den Boom, Martin Vescovo, Marisa Viggiani, Pietro Visca, Dina Zhurkin, Dmitry Zignol, Matteo RA Aspectos Públicos de la Medicina The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline Elsevier Science 2019 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/23472/1/23472.pdf http://eprints.uanl.mx/23472/1.haspreviewThumbnailVersion/23472.pdf Akkerman, Onno y Aleksa, Alena y Alffenaar, Jan Willem y Al-Marzouqi, Nada Hassan y Arias Guillén, Miguel y Belilovski, Evgeny y Bernal, Enrique y Boeree, Martin J. y Borisov, Sergey y Bruchfeld, Judith y Cadiñanos Loidi, Julen y Cai, Qingshan y Caminero, Jose A. y Cebrian Gallardo, Jose Joaquín y Centis, Rosella y Codecasa, Luigi Ruffo y D’Ambrosio, Lia y Dalcolmo, Margareth Pretti y Danila, Edvardas y Dara, Masoud y Davidavičienė, Edita y Davies Forsman, Lina y De Los Rios Jefe, Jorge y Denholm, Justin y Duarte, Raquel y Elamin, Seifeldin Eltaeb y Ferrarese, Maurizio y Filippov, Alexey y Ganatra, Shashank y Garcia, Ana y García García, José María y Gayoso, Regina y Giraldo Montoya, Angela Maria y Gómez Rosso, Roscio Gómez y Gualano, Gina y Hoefsloot, Wouter y Ilievska Poposka, Biljana y Jonsson, Jerker y Khimova, Elena y Kuksa, Liga y Kunst, Heinke y Laniado Laborín, Rafael y Li, Yang y Magis Escurra, Cecile y Manfrin, Vinicio y Manga, Selene y Marchese, Valentina y Martínez Robles, Elena y Maryandyshev, Andrei y Matteelli, Alberto y Migliori, Giovanni Battista y Mullerpattan, Jai B. y Muñoz Torrico, Marcela y Mustafa Hamdan, Hamdan y Nieto Marcos, Magnolia y Noordin, Noorliza Mohamad y Palmero, Domingo Juan y Palmieri, Fabrizio y Payen, Marie Christine y Piubello, Alberto y Pontali, Emanuele y Pontarelli, Agostina y Quirós, Sarai y Rendón, Adrián y Skrahina, Alena y Smite, Agnese y Solovic, Ivan y Sotgiu, Giovanni y Souleymane, Mahamadou Bassirou y Spanevello, Antonio y Stošić, Maja y Tadolini, Marina y Tiberi, Simon y Udwadia, Zarir Farokh y Van den Boom, Martin y Vescovo, Marisa y Viggiani, Pietro y Visca, Dina y Zhurkin, Dmitry y Zignol, Matteo (2019) Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 83. pp. 72-76. ISSN 12019712 http://doi.org/10.1016/j.ijid.2019.03.036 doi:10.1016/j.ijid.2019.03.036 |
| spellingShingle | RA Aspectos Públicos de la Medicina Akkerman, Onno Aleksa, Alena Alffenaar, Jan Willem Al-Marzouqi, Nada Hassan Arias Guillén, Miguel Belilovski, Evgeny Bernal, Enrique Boeree, Martin J. Borisov, Sergey Bruchfeld, Judith Cadiñanos Loidi, Julen Cai, Qingshan Caminero, Jose A. Cebrian Gallardo, Jose Joaquín Centis, Rosella Codecasa, Luigi Ruffo D’Ambrosio, Lia Dalcolmo, Margareth Pretti Danila, Edvardas Dara, Masoud Davidavičienė, Edita Davies Forsman, Lina De Los Rios Jefe, Jorge Denholm, Justin Duarte, Raquel Elamin, Seifeldin Eltaeb Ferrarese, Maurizio Filippov, Alexey Ganatra, Shashank Garcia, Ana García García, José María Gayoso, Regina Giraldo Montoya, Angela Maria Gómez Rosso, Roscio Gómez Gualano, Gina Hoefsloot, Wouter Ilievska Poposka, Biljana Jonsson, Jerker Khimova, Elena Kuksa, Liga Kunst, Heinke Laniado Laborín, Rafael Li, Yang Magis Escurra, Cecile Manfrin, Vinicio Manga, Selene Marchese, Valentina Martínez Robles, Elena Maryandyshev, Andrei Matteelli, Alberto Migliori, Giovanni Battista Mullerpattan, Jai B. Muñoz Torrico, Marcela Mustafa Hamdan, Hamdan Nieto Marcos, Magnolia Noordin, Noorliza Mohamad Palmero, Domingo Juan Palmieri, Fabrizio Payen, Marie Christine Piubello, Alberto Pontali, Emanuele Pontarelli, Agostina Quirós, Sarai Rendón, Adrián Skrahina, Alena Smite, Agnese Solovic, Ivan Sotgiu, Giovanni Souleymane, Mahamadou Bassirou Spanevello, Antonio Stošić, Maja Tadolini, Marina Tiberi, Simon Udwadia, Zarir Farokh Van den Boom, Martin Vescovo, Marisa Viggiani, Pietro Visca, Dina Zhurkin, Dmitry Zignol, Matteo Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| title_full | Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| title_fullStr | Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| title_full_unstemmed | Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| title_short | Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study |
| title_sort | surveillance of adverse events in the treatment of drug resistant tuberculosis a global feasibility study |
| topic | RA Aspectos Públicos de la Medicina |
| url | http://eprints.uanl.mx/23472/1/23472.pdf |
| work_keys_str_mv | AT akkermanonno surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT aleksaalena surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT alffenaarjanwillem surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT almarzouqinadahassan surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT ariasguillenmiguel surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT belilovskievgeny surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT bernalenrique surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT boereemartinj surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT borisovsergey surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT bruchfeldjudith surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT cadinanosloidijulen surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT caiqingshan surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT caminerojosea surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT cebriangallardojosejoaquin surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT centisrosella surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT codecasaluigiruffo surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT dambrosiolia surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT dalcolmomargarethpretti surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT danilaedvardas surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT daramasoud surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT davidavicieneedita surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT daviesforsmanlina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT delosriosjefejorge surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT denholmjustin surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT duarteraquel surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT elaminseifeldineltaeb surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT ferraresemaurizio surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT filippovalexey surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT ganatrashashank surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT garciaana surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT garciagarciajosemaria surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT gayosoregina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT giraldomontoyaangelamaria surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT gomezrossorosciogomez surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT gualanogina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT hoefslootwouter surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT ilievskapoposkabiljana surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT jonssonjerker surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT khimovaelena surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT kuksaliga surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT kunstheinke surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT laniadolaborinrafael surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT liyang surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT magisescurracecile surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT manfrinvinicio surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT mangaselene surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT marchesevalentina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT martinezrobleselena surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT maryandyshevandrei surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT matteellialberto surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT migliorigiovannibattista surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT mullerpattanjaib surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT munoztorricomarcela surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT mustafahamdanhamdan surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT nietomarcosmagnolia surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT noordinnoorlizamohamad surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT palmerodomingojuan surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT palmierifabrizio surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT payenmariechristine surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT piubelloalberto surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT pontaliemanuele surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT pontarelliagostina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT quirossarai surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT rendonadrian surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT skrahinaalena surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT smiteagnese surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT solovicivan surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT sotgiugiovanni surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT souleymanemahamadoubassirou surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT spanevelloantonio surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT stosicmaja surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT tadolinimarina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT tiberisimon surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT udwadiazarirfarokh surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT vandenboommartin surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT vescovomarisa surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT viggianipietro surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT viscadina surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT zhurkindmitry surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy AT zignolmatteo surveillanceofadverseeventsinthetreatmentofdrugresistanttuberculosisaglobalfeasibilitystudy |